Niagen Bioscience (NAGE) Corporate presentation summary

Strategic focus and scientific leadership

• Developing therapies for rare genetic diseases and aging-related disorders, leveraging expertise in NAD+ research with over 25 years of preclinical and clinical experience.

• Scientific advisory board led by leading NAD+ metabolism experts, guiding rare disease strategy.

• Cash flow positive NAD+ platform business supports ongoing development.

Lead program: NB4168 for ataxia telangiectasia (A-T)

• NB4168 is a novel, patented molecule designed for higher bioavailability and improved therapeutic index compared to NR.

• Preclinical studies show NB4168 is 10x more bioavailable than NR and releases more active moiety systemically.

• Oral formulation is being developed for pediatric patients.

Clinical evidence and therapeutic rationale

• NAD+ depletion is implicated in A-T pathology; restoring NAD+ may compensate for ATM gene loss and improve outcomes.

• Two independent clinical trials with NR in A-T patients showed improved neuromotor function and coordination, supporting NB4168's development.